US EditionBreakthrough male birth control pill passes safety test in early clinical trial
- A new male contraceptive pill that does not rely on hormones, known as YCT-529, successfully completed its initial safety evaluation in a phase 1 clinical study published on July 22.
- Researchers conducted this trial with 16 vasectomized men aged 32 to 59 to test the drug's safety and body absorption without assessing contraceptive efficacy.
- The study found no significant side effects on heart rate, hormone levels, mood, sexual desire, liver or kidney function after doses ranging from 10mg to 180mg.
- YCT-529 works by blocking retinoic acid receptor-alpha to pause sperm production and showed reversible infertility with no lasting effects in animal studies, as noted by the researchers.
- These results enable larger trials to test safety and efficacy, potentially adding a much-needed male contraceptive option beyond condoms and vasectomies.
Insights by Ground AI
Does this summary seem wrong?
33 Articles
33 Articles
The new study showed that YCT-529 was well tolerated at increasing doses, meeting some of the basic requirements for the development of a male contraceptive.
·Bratislava, Slovakia
Read Full Article
Hormone-free male contraceptive pill passes first safety test
The male contraceptive pill just completed phase 1 trials. Pixel-Shot/ ShutterstockA potential new male contraceptive drug has just undergone its first tests in human volunteers. The results give the first indication that the drug, which does not use artificial hormones or affect testosterone production by the testes, may be safe in humans. While previous attempts have been made to develop a male contraceptive in the past, these largely failed t…
Coverage Details
Total News Sources33
Leaning Left2Leaning Right5Center12Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
11%
C 63%
R 26%
Factuality
To view factuality data please Upgrade to Premium
